Bristol Meyers Squibb vs Takeda Vidhya Nagabhushans
Antitrust laws were essentially created to stop businesses that got too large from blocking competition and abusing their power. Mergers and monopolies can limit the choices offered to consumers because smaller businesses are not usually able to compete. Although free and open competition ensures lower prices and new and better products, it has the potential to significantly limit market diversity. Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to
…show more content…
Health care reforms should not rely on price controls or government regulation to control costs. Such efforts can adversely affect the development of new medical advances because they cap the potential for an appropriate return on investment and can restrict access to advanced therapies. Instead, allowing robust competition in the marketplace, coupled with strong patent protection, is the best and most efficient way to restrain health care and pharmaceutical costs, while ensuring the next wave of medical advances. The types of legal barriers to market entry exist are Research and development is the heart and soul of Bristol-Myers Squibb. The Discovery and Exploratory Clinical Research group represents the beginning of that process. Our goal is to discover drugs and conduct early stage clinical studies to show the value of those drugs, evaluate their safety and determine how they work. As ground-breaking science and external market factors continue to evolve, innovation will play an increasingly critical role in maintaining competitive advantage. In Discovery, we continuously strive for innovation not only in our pipeline but also in our processes; we focus on how we can deliver value to the patient. For example, we evaluate the use of technology to improve the speed and efficiency of our business practices, operations, and transitions of potential drugs to development.